Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2020 / Jul / Business in Brief (1)
Oncology Genetics and epigenetics Oncology Technology and innovation Infectious Disease Molecular Pathology

Business in Brief

The latest business news in the world of diagnostic medicine

By Luke Turner 07/15/2020 Quick Read (pre 2022) 1 min read

Share

A PCR-based test for determining microsatellite instability (MSI) status in solid tumors has received the CE mark as a new in vitro diagnostic medical device. OncoMate™ MSI provides a DNA-based MSI reading complementary to a standard MMR immunohistochemistry panel, which can be used to predict response to immuno-oncology therapies (1).

Quantum Leap Healthcare Collaborative has selected Byondis B.V.’s investigational antibody-drug conjugate, SYD985, in its ongoing I-SPY 2 TRIAL™ for neoadjuvant breast cancer treatment. The trial aims to rapidly screen and identify promising treatments in specific subgroups of women with newly diagnosed, high-risk, and locally advanced cancer (2).

A new type of predictive test for osteoporosis provides early insights into the bone mineral balance of the human body using a urine or blood sample. In a study of 100 women, the OsteoTest predicted fractures caused by bone atrophy more accurately and less invasively than current X-ray-based methods (3).

Beckman Coulter’s Access SARS-CoV-2 IgG assay has received Emergency Use Authorization from the US Food and Drug Administration. The assay, which is in over 400 hospitals, clinics, and diagnostic laboratories in the US, will now be distributed worldwide – and the company says it can produce over 30 million tests every month (4).

An analysis of 929 genomes from patients who responded poorly to COVID-19 has revealed 68 genes associated with severe disease. Researchers hope the genes – nine of which are already targets of drugs that have reached at least Phase I clinical trials – will inform the development of biomarker-driven tests and new therapeutic strategies (5).

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Promega (2020). Available at: https://bit.ly/2DzIMHi.
  2. Byondis (2020). Available at: https://bit.ly/3iTRVdY.
  3. Osteolabs (2020). Available at: https://bit.ly/2OgIPK7.
  4. Beckman Coulter (2020). Available at: https://prn.to/2C4zSkF.
  5. S Ghafouri-Fard et al., 128, 110296 (2020). PMID: 32480226.

About the Author(s)

Luke Turner

While completing my undergraduate degree in Biology, I soon discovered that my passion and strength was for writing about science rather than working in the lab. My master’s degree in Science Communication allowed me to develop my science writing skills and I was lucky enough to come to Texere Publishing straight from University. Here I am given the opportunity to write about cutting edge research and engage with leading scientists, while also being part of a fantastic team!

More Articles by Luke Turner

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Breathing New Life into Diagnostics
Genetics and epigenetics
Breathing New Life into Diagnostics

January 22, 2024

6 min read

Jonathan Edgeworth on how metagenomics could transform testing for respiratory infections

Molecular Spectacular
Genetics and epigenetics
Molecular Spectacular

January 8, 2024

1 min read

A look at last year’s most interesting molecular pathology stories

Redefining Diagnostic Reference Standards
Genetics and epigenetics
Redefining Diagnostic Reference Standards

January 3, 2022

1 min read

Find out what Horizon Discovery’s diagnostic reference standards can do for your workflow

Defining the Next Generation of NGS
Genetics and epigenetics
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.